Drug firm co-operating with Philippines government amid dengue vaccine fears
The manufacturer of a dengue fever vaccine that was suspended in the Philippines after a study showed a greater risk of severe cases in people not previously infected has said it is working with authorities to address fears and share the new information.
The Department of Health put on hold its 3.5 billion peso (£51.5 million) public dengue immunisation drive launched last year- the world's first such public programme - after the research was released last week.
French-based Sanofi Pasteur said its long-term follow-up study of its Dengvaxia vaccine showed sustained benefits for up to six years for those who had previous dengue infection, but that people who never had dengue had an increased risk of a severe case and hospital admission from the third year after immunisation.
More than 730,000 schoolchildren aged nine and above in three Philippine regions with high rates of dengue fever have received at least the first dose of Dengvaxia, the first licensed dengue vaccine.
"Today, if you know somebody without previous infection, we would not recommend vaccination," said Dr Ng Su-Peing, global medical head at Sanofi Pasteur.
Nevertheless, she said, in places with a high incidence of dengue fever, such as the Philippines, where nine out of 10 children aged nine to 14 are infected by the virus before adolescence, "the potential benefits of vaccination outweigh the potential risks in individuals with unknown serostatus".
Out of 100 people infected by dengue, only 25 typically show symptoms, she told reporters.
Ms Ng said most participants in the study without previous dengue infection who fell ill had cases that ranked in the milder two of four levels of severity. No cases in the most severe level were recorded, and all those stricken with dengue in the study have fully recovered, she said.
Health Secretary Francisco Duque III said the Philippines will wait for a recommendation to be released on December 12 or 13 by the Strategic Advisory Group of Experts on Immunisation, an advisory body of the World Health Organisation.
Ching Santos, general manager of Sanofi Pasteur in the Philippines, said the company has begun sharing the new data with all stakeholders, including private healthcare professionals, and will co-operate with Philippines health authorities in an ongoing review of the public vaccination programme.
Sanofi is also working with the Philippines Food and Drugs Administration to update product labels to reflect the new information, she added.
Dengue is a mosquito-borne viral infection found in tropical and subtropical climates worldwide. It results in a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can cause breathing problems, haemorrhaging and organ failure.
The World Health Organisation says about half the world's population is at risk of dengue, with a recent estimate indicating 390 million infections per year, of which about 96 million people show symptoms.